Emerging treatments
Intravitreal sirolimus
Offers several potential advantages over existing approved treatments for noninfectious uveitis, and is currently undergoing clinical trials. It is a mammalian target of rapamycin (mTOR) inhibitor with immunosuppressant properties. It avoids ocular complications such as cataracts associated with corticosteroid treatment, and can be injected using a smaller gauge needle. Phase II trials have shown that it is effective in controlling uveitis and reducing macular edema due to diabetic retinopathy.[45]
Tocilizumab
Tocilizumab is a humanized monoclonal antibody directed against interleukin-6. This medication is helpful in the management of systemic juvenile idiopathic arthritis, but its role in associated uveitis remains less established.[46] At present, it may be considered as an adjunctive therapy in cases of noninfectious uveitis refractory to tumor necrosis factor-alpha inhibitors.[38][47]
Use of this content is subject to our disclaimer